

Predictors of Loss to Follow-up Among HIV-infected Patients in a Rural South-Eastern Nigeria Hospital: A 5-year Retrospective Cohort Study

Eguzo KN, Lawal AK¹, Umezurike CC², Esegbe CE³

Department of Academic Family Medicine, University of Saskatchewan, ¹College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada, Departments of ²Obstetrics and Gynecology and ³Laboratory Services, Nigerian Christian Hospital, Nlaga, Nigeria

Address for correspondence:

Dr. Eguzo KN,
Department of Academic
Family Medicine, University of
Saskatchewan, 172-1621 Albert Street,
Regina, SK S4P 2S5,
Saskatchewan, Canada.
E-mail: kelechi.eguzo@usask.ca

Abstract

Background: Patient attrition has been a challenge in managing HIV programs in resource-limited settings. **Aim:** This study reviews the predictors of loss to follow-up (LTFU) in our hospital and suggests the best practices for dealing with the issue. **Subjects and Methods:** A 5-year retrospective cohort study of 1256 HIV-infected patients. Baseline CD4 counts, age, gender, year of enrolment, and antiretroviral therapy combination regimen were considered in this study. Kaplan–Meier models were used to estimate the univariate time-to-LTFU and Cox proportional hazards models to identify the multivariate predictors of LTFU. **Results:** Twenty-four percent (23.9% [301/1256]) of patients were lost to follow-up. Baseline CD4 count, year of enrolment, and drug combination were significant predictors of LTFU. Patients enrolled earlier (2008/2009) were twice as likely to be LTFU compared with those enrolled later (2010–2013). Gender and age did not significantly predict LTFU nor confound other predictors. **Conclusion:** The program showed higher LTFU rates than most studies in Nigeria and Africa, maybe due to difficulties with the access to the hospital and possible treatment fatigue. This study recommends the provision of transportation subsidies and proactive patient follow-up with “peer-tracking” to reduce LTFU among HIV infected patients, especially in resource-limited settings.

Keywords: Cohort studies, HIV infections, Loss to-follow-up, Nigeria, Transportation

Introduction

In the last decade, Nigeria has scaled up the antiretroviral program for people living with HIV. The number of people accessing antiretroviral therapies (ARTs) rose from 10,000 (2002) to 300,000 (2010), especially through the U.S President’s Emergency Plan for AIDS Relief.^[1] Our hospital was activated in August 2008 to provide ART services in south-eastern Nigeria. Despite this free treatment, it is surprising that many patients still dropped out of the various programs at this facility. Rates of the loss to follow-up (LTFU) in

resource-limited settings such as ours reported in the literature range from 16% to 40%.^[2–4] Onoka *et al.* studied HIV programs in South-eastern Nigeria and reported LTFU rate between 11% and 32.8%.^[5]

Researchers have shown that LTFU among HIV-infected patients in resource-limited settings is significantly associated with being male, baseline CD4 count <200/ μ L, age <35 years and

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Eguzo KN, Lawal AK, Umezurike CC, Esegbe CE. Predictors of loss to follow-up among HIV-infected patients in a rural South-Eastern Nigeria Hospital: A 5-year retrospective cohort study. *Ann Med Health Sci Res* 2015;5:373-8.

Access this article online

Quick Response Code:



Website: www.amhsr.org

DOI:
10.4103/2141-9248.177988

with stavudine containing first line regimen.^[2] Few studies have been conducted to research into the predictors of LTFU in this region of Nigeria. Onoka *et al.* reported that LTFU for patients in South-eastern Nigeria was more likely for males, patients with CD4 count $\leq 200/\mu\text{L}$ and enrollees of programmes in public hospitals.^[5] The follow-up period for this particular study was rather short (median 14 months), and did not consider the differences, based on treatment regimens throughout the follow-up time.

LTFU has been shown to contribute to poorer health outcome for patients and constitutes resource wastage, as well as the promotion of HIV drug resistance.^[2,5] Research, however, has not differentiated LTFU rates between patients on ART and non-ART. Also, the rate of LTFU could be utilized as an index of program effectiveness with respect to patient tracking.^[6] This study aims to identify the predictors of LTFU in a rural hospital, and to highlight best practices in improving patient retention in similar settings.

Subjects and Methods

Study setting and participants

This study was conducted at Nigerian Christian Hospital (NCH), Aba-Nigeria; a rural 110-bed faith-based hospital affiliated with the Churches of Christ and International Health Care Foundation. Since August 2008, more than 3000 HIV-infected people have been enrolled in its program. This program offers the voluntary counselling and testing, prevention-of-mother-to-child-transmission, pediatric and non-pediatric ARTs, as well as immunology services. Currently, there are about 2000 clients on treatment, and about 40 clients are seen each day in clinic. The majority of patients enrolled in the program were recruited through antenatal care, voluntary testing, referral and in-patient hospitalization. A team of doctors, nurses, community health officers as well as monitoring and evaluation staff ensured patient follow-up and tracking of appointments. The hospital also offers specialist services in surgery, ophthalmology, oncology, internal medicine as well as obstetrics and gynaecology.^[7]

According to the NCH treatment protocol, patients were considered eligible for ART if they were in the WHO clinical Stage 3 or 4 irrespective of CD4 cell count; if they were pregnant irrespective of CD4 count, and if they had a CD4+ cell count ≤ 350 cells/ μL . Details of other treatment criteria were per the National and WHO guidelines.^[1,8] Follow-up appointments ranged from fortnightly to quarterly, depending on the progression of the clinical disease, adherence profile, and prevailing circumstance. They were monitored for adherence and retention through home visits, frequent phone calls as well as attendance at support group meetings. Monitoring was conducted through the IQ Care software (Futures Group, Washington D.C, USA).

This research is a retrospective cohort study of HIV patients aged 15 years or older who were enrolled at the NCH between

August 1, 2008, and October 25, 2013. The inclusion criteria were; (1) subjects must be HIV positive, ≥ 15 years of age and (2) enrolled at NCH. It excluded the patients who were transferred to other treatment facilities during the study period. Approval for the study was obtained from the Board of NCH. Patient confidentiality was maintained by using anonymized data extracted from the database.

Treatment, monitoring and endpoints

NCH program uses Truvada and Combivir based Highly Active Antiretroviral Therapy. First line treatment includes a combination of lamivudine-3TC and zidovudine (ZDV) (Combivir), with either nevirapine (NVP), or efavirenz (EFV). Truvada® (emtricitabine [FTC]/tenofovir [TDV]) with either NVP or EFV is also a first line. Regimen choice was based on baseline CD4 count, pregnancy status, tuberculosis co-infection, and previous ARTs exposure. Co-trimoxazole prophylaxis (960 mg q.d.) was provided to patients with CD4 ≤ 400 cells/ μL . Following ART initiation, patients were followed up for 2 weeks to monitor for drug reactions and assess adherence. Subsequently, ARTs were dispensed on a monthly basis. With consistent adherence and follow-up, patients who were considered stable were given 2-monthly appointment schedules. Second line therapy was provided to clients who had clinical, or virologic failure on first-line therapy. The 2nd line therapy included a combination of lopinavir/ritonavir (Kaletra®, Aluvia®-ALV) with either Truvada® or Combivir®. For the purpose of this research, these combinations were categorized as Combivir-based first line (3TC/ZDV with EFV or NVP); Truvada-based first line (TDV/FTC with EFV or NVP); Combivir-based second line (3TC/ZDV with ALV), and Truvada-based second line (TDV/FTC with ALV).

This study considered the immunologic classification of the disease using baseline CD4 count, based on WHO criteria.^[9] Patients were classified as follows: CD4 $\geq 500/\mu\text{L}$ – “not significant disease;” 350–499/ μL – “mild disease;” 200–349/ μL – “advanced disease” and $< 200/\mu\text{L}$ – “severe disease.” Age at enrolment was further classified as 15–24 years; 35–44 years, and ≥ 45 years; in line with the classification used in peer-reviewed literature.^[10-12] Table 1 shows the baseline characteristics of patients included in the study.

LTFU, the main endpoint in this study, was defined as a patient who missed an appointment for more than 6 months after the last visit and could not be traced until the end of the study period.^[13] The date of the last visit was taken as the date of the event. Patients were considered censored, if dead (based on reported date or last visit date) or if they were alive at the end of the study period (October 25, 2013).

Statistical analysis

The dependent variable in this study is the patient's status, categorized as either dead, alive, transferred, or LTFU. Univariable Kaplan–Meier analysis was performed at $\alpha = 0.05$

level to determine the independent predictors of LTFU using sex, year of enrolment, age group, baseline WHO CD4 category, treatment program, and drug combination. Significant baseline variables in the univariable analysis were included in the final multivariable model. All other analyses were two-sided, and level of significance was set at $P < 0.05$. Statistical analysis was done using SAS version 9.3. (SAS Institute Inc., Cary, NC, USA). Kaplan–Meier method was used to estimate the retention rates after ART initiation, and log-rank tests to compare the survival curves. Cox proportional hazards models were used to identify the predictors of LTFU and calculate the hazard ratios (HRs). The survival time was calculated in months using the time interval between the date of enrolment and (1) the date of the event (LTFU) or (2) date of censoring.

Results

A total of 1256 patients were eligible for this study, comprising 68.3% (858/1256) females and 31.7% (398/1256) males. The median age in the study was 37 years; males 41 years and females 35 years, respectively. 23.9% (307/1256) patients were lost to follow-up during the 5-year period after enrolment in the program while 76% (955/1256) were censored. Table 2 shows the baseline characteristics of study population. The median LTFU time for non-ART clients was 1-month while those on ART could be not estimated as the majority of the observations were censored. In total, those LTFU comprised 36.8% (107/307) males and 64.5% (194/307) females. Based on age, those LTFU comprised 5.6% (17/307) aged 15–24; 38.2% (115/307) aged 25–34; 36.2% (109/307) aged 35–44, and 19.9% (60/307) aged above 45 years. In terms of the year of enrolment, the highest proportion of patients LTFU (32.9% [99/307]) was recorded in 2009. LTFU was most common among the patients with baseline CD4 $< 200/\mu\text{L}$ (82.4% [253/307]) and lowest among those with baseline CD4 counts of 200–349/ml, 3.3% (10/307). LTFU was more prominent among patients taking Truvada-based first line agents 28.7% (88/307) compared with 18.9% (58/307) for those on the Combivir-based first line. At the end of the study period, 955 patients were censored comprising 10.2% (97/955) deaths and 89.8% (858/955) alive.

Based on the univariable analysis, baseline CD4 count [Figure 1], year of enrolment [Figure 2], drug combination [Figure 3], and treatment program (ART, non-ART) [Figure 4] were significant predictors of LTFU. Gender and age did not significantly predict LTFU and did not interact/confound the other predictors. Table 3 shows the univariable and multivariable analyses.

Discussion

This 5-year retrospective cohort study of people living with HIV/AIDS sheds light on the concept of LTFU and its determinants in a program administered in a rural Nigerian hospital. Previous studies found that the male patients were

Table 1: Baseline characteristics and the proportion of LTFU among 1256 HIV patients in NCH

Characteristics	Number of patients	Number LTFU (%)
LTFU	301 (23.9%)	
Gender		
Male	398	107 (35.6)
Female	858	194 (64.5)
Enrolment year		
2008	156	46 (15.3)
2009	341	99 (32.9)
2010	173	38 (12.6)
2011	255	52 (17.3)
2012	216	56 (18.6)
2013	115	10 (3.3)
Care program		
ART	1045	157 (52.2)
Non-ART	190	133 (44.2)
Age group (years)		
15-24	51	17 (5.65)
25-34	422	115 (38.2)
35-44	508	109 (36.2)
45+	275	60 (19.9)
Baseline CD4 staging (cells/ μL)		
>500	183	73 (24.3)
350-499	174	40 (13.3)
200-349	325	54 (17.9)
<200	594	134 (44.5)
200-349	156	10 (3.3)
<200	594	253 (84.1)
Drug regimen		
Combivir-based first line	383	58 (19.3)
Truvada-based first line	547	88 (29.2)
Combivir-based second line	66	6 (2)
Truvada-based second line	53	4 (1.3)


LTFU: Loss to follow-up, NCH: Nigerian Christian Hospital, ART: Antiretroviral therapy

Table 2: Last know status of HIV patients NCH included in the study

Last known status	Number (%)
Dead	97 (7.7%)
Alive	858 (68.3%)


NCH: Nigerian Christian Hospital

more likely to suffer attrition; our study did not find any significant difference in LTFU rates based on age and gender, and these were neither confounding nor interacting with any other predictors considered in the study. However, we found that the patients who were enrolled earlier in the program (2008 and 2009) were at least twice more likely than those enrolled later (2010–2013) to be lost to follow-up. Hazard of LTFU for patients enrolled in 2008 was 3 times higher than 2013 enrollees (HR 3.1 95% confidence interval [CI] 1.16–8.17; $P = 0.02$), while the hazard for those enrolled in 2009 was 2 times higher (HR 2.69 95% CI 1.05–6.88, $P = 0.04$). Baseline CD4 counts and drug combinations were not found to be significant predictors of LTFU in this study.



Log rank $P=0.01$

Figure 1: Kaplan–Meier curves for loss to follow-up based on patient class




Combination1 (Combivir 1st line)
Combination 2 (Truvada 1st line)
Combination 3 (Combivir 2nd line)
Combination 4 (Truvada 2nd line)
Log rank $P=0.09$

Figure 3: Kaplan–Meier curves for loss to follow-up based on drug combination regimen


Overall, our LTFU rate was more than twice the value reported by Onoka *et al.*, who compared patient attrition between public and private institutions.^[5] Several factors could be responsible for this; the functioning of the hospital was adversely affected by insecurity between 2009 and 2012 due to kidnapping that was rampant in our community. In addition, the access road to the hospital has been in a state of disrepair for more than 3 years. The difficulty in accessing treatment due to transportation difficulties could have discouraged a good number of our patients.

Although the adjusted hazards for patients on ART compared to non-ART patient was not significant, the univariable analysis



CD4 stage 1 (≥ 500 cells/ μ L)
CD4 stage 2 (350-499 cells/ μ L)
CD4 stage 3 (200-349 cells/ μ L)
CD4 stage 4 (<200 cells/ μ L)
Log rank $P<0.001$

Figure 2: Kaplan–Meier curves for loss to follow-up based on baseline CD4 class



Log rank $P=0.01$

Figure 4: Kaplan–Meier curves for loss to follow-up based on year of enrolment

may help to draw our attention to the concept of “treatment fatigue” among HIV patients. Treatment fatigue describes the psychological exhaustion of patients with chronic diseases, who have to take numerous pills over a long time. Further research should be conducted to explore this concept and its impact on rates of LTFU among HIV patients.

Toward reduction of LTFU among HIV patients: Review of best practices.

Understanding the causes of patient attrition and improving retention in care is challenging in resource-limited-settings.^[14] Evidence shows that improved documentation can impact

Table 3: HRs of LTFU according to predictors for HIV patients in NCH

Variable	Unadjusted (univariable)		Adjusted (multivariable)	
	HR (95% CI)	P	HR (95% CI)	P
Baseline CD4 staging (vs. >500 cells)				
<200	0.60 (0.45-0.79)	<0.001	1.00 (0.62-1.62)	0.99
200-349	0.54 (0.37-0.80)	<0.001	0.42 (0.21-0.85)	0.02
350-499	0.40 (0.27-0.55)	<0.001	0.75 (0.44-1.27)	0.28
Drug combination				
Truvada versus Combivir first line	0.95 (0.68-1.33)	0.78	0.82 (0.58-1.16)	0.26
Truvada versus Combivir second line	0.90 (0.25-3.20)	0.88	0.95 (0.27-3.34)	0.94
Enrolment year (vs. 2008)				
2009	1.02 (0.72-1.45)	0.89	0.87 (0.56-1.36)	0.55
2010	0.76 (0.50-1.17)	0.30	0.53 (0.30-0.96)	0.03
2011	0.74 (0.50-1.11)	0.14	0.41 (0.23-0.73)	<0.001
2012	1.06 (0.71-1.57)	0.76	0.66 (0.58-1.15)	0.14
2013	0.44 (0.22-0.87)	0.02	0.33 (0.12-0.86)	0.02

NCH: Nigerian Christian Hospital, LTFU: Loss to follow-up, HRs: Hazard ratios, CI: Confidence interval

patient attrition. Some patients have been known to be lost to follow-up in one facility, only to end up in another facility as clients.^[14] We think it is necessary to improve local documentation and share medical records (to some extent) for patients receiving ART. This can be achieved through greater collaboration among treatment providers in a geographic area. Nigeria has moved toward this by streamlining the coordination of treatment providers under two broad programs; this makes records sharing easy.

Also, the model of treatment programs is crucial in improving patient retention. Although Geng *et al.* found that LTFU was about 8-fold higher in larger, centralized treatment centers compared to smaller centers. This may not be unconnected with the difficulty in monitoring a large pool of patients, especially in resource-limited settings. Although there is no definition of “large centers,” our experience in NCH suggests that the programs with more than 2000 clients may be more prone to higher LTFU rates. It may be important to limit the size of individual treatment programs to below 2000. This will lead to the activation of more treatment sites that will be closer to the clients’ communities, thus improving tracking. It may also handle the challenge of tracking non-ART patients, who are historically more likely to be lost to follow-up, even in NCH.^[14] Retention is also higher for programs with peer group support (such as the support group meetings at NCH) and outreach services (such as home visits).^[14]

Meanwhile, many patients experience the transportation difficulties, maybe due to the poor condition of roads (like in NCH), or poverty. Travel times longer than 2 hours have been associated with double LTFU rates.^[15] Emenyonu *et al.* found that the patients who received transportation subsidy were significantly less likely to be LTFU.^[16] This suggests that the programs may benefit from some form of transportation subsidy. Evidence also suggests that the patients with strong social support are less likely to

abandon treatment.^[14] NCH has a vibrant support group for our clients, and this improves “peer-tracking.” Etienne *et al.* reviewed the treatment programs in 27 low-income countries, and found that sites with “proactive follow-up” models, such as home visits, had lower rates of LTFU.^[17] These suggestions are not exhaustive, but only go to show some approaches that are successful. With the rapid penetration of mobile technology in Africa, we encourage program managers to explore its use in patient tracking and retention.

Study limitations

This study is limited because of the sampling strategy. Including all eligible patients provided a skewed sample that made it difficult to explore some statistical quantities. We did not explore other variables that could influence patient retention such as the effect of travel time, social support, and home visits on LTFU at NCH and inability to capture the washout period before switching to second-line antiretroviral agents made it difficult to draw comparisons between levels of therapy.

Conclusion

The study was conducted to identify the determinants of LTFU in a retrospective cohort of HIV patients followed for 60 months. We have shown that people enrolled earlier in the program are more likely to drop out of treatment, thus helping program managers to better focus their interventions on LTFU. Although an observed difference was identified for patients on ART compared to non-ART patients, this difference was not significant when other factors were considered in the adjusted model. Further research is needed to explore the concept of “treatment fatigue” as a factor in LTFU for patients receiving HIV treatment. HIV program managers are also encouraged to intensify the follow-up strategies for patients on ART medications in their programs.

Acknowledgement

The authors acknowledge the support of the staff at the Monitoring and Evaluation Unit of Nigerian Christian Hospital as well as the hospital board towards the success of this work.

Financial support and sponsorship

Private.

Conflicts of interest

There are no conflicts of interest.

References

1. Federal Ministry of Health: National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults; 2010. Available from: http://www.who.int/hiv/pub/guidelines/nigeria_art.pdf. [Last accessed on 2014 Jun 21].
2. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, *et al.* Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: A longitudinal analysis for risk factors. *PLoS One* 2010;5:e10584.
3. Messou E, Kouakou M, Gabillard D, Gouessé P, Koné M, Tchehy A, *et al.* Medication possession ratio: Predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'Ivoire. *J Acquir Immune Defic Syndr* 2011;57 Suppl 1:S34-9.
4. Hønge BL, Jespersen S, Nordentoft PB, Medina C, da Silva D, da Silva ZJ, *et al.* Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: A 7-year retrospective cohort study. *BMJ Open* 2013;3:e003499.
5. Onoka CA, Uzochukwu BS, Onwujekwe OE, Chukwuka C, Ilozumba J, Onyedum C, *et al.* Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. *Pathog Glob Health* 2012;106:46-54.
6. Ware NC, Wyatt MA, Geng EH, Kaaya SF, Agbaji OO, Muyindike WR, *et al.* Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: A qualitative study. *PLoS Med* 2013;10:e1001369.
7. Eguzo KN, Lawal AK, Esegbe CE, Umezurike CC. Determinants of mortality among adult HIV-infected patients on antiretroviral therapy in a rural hospital in Southeastern Nigeria: A 5-year cohort study. *AIDS Res Treat* 2014;2014:867827.
8. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach; 2010 Revision.
9. WHO. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. Geneva: WHO; 2007. Available from: <http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf>. [Last accessed on 2014 Nov 02].
10. Ogoina D, Obiako RO, Muktar HM, Adeiza M, Babadoko A, Hassan A, *et al.* Morbidity and mortality patterns of hospitalised adult HIV/AIDS patients in the era of highly active antiretroviral therapy: A 4-year retrospective review from Zaria, Northern Nigeria. *AIDS Res Treat* 2012;2012:940580.
11. Alemu AW, Sebastián MS. Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. *Glob Health Action* 2010;3:5398
12. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, *et al.* Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. *BMC Infect Dis* 2008;8:52.
13. Chi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, *et al.* Universal definition of loss to follow-up in HIV treatment programs: A statistical analysis of 111 facilities in Africa, Asia, and Latin America. *PLoS Med* 2011;8:e1001111.
14. Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, *et al.* Retention in care among HIV-infected patients in resource-limited settings: Emerging insights and new directions. *Curr HIV/AIDS Rep* 2010;7:234-44.
15. Rabkin M, Austin J, Nash D. High Patient Retention Rates in a Multinational HIV/AIDS Treatment Program: The Columbia University Mother-to-Child-Plus Experience. In: 17th Conference on Retroviruses and Opportunistic Infections San Francisco, CA; 2010.
16. Emenyonu N, Muyindike W, Habyarimana J, Pops-Eleches C, Thirumurthy H. Cash Transfers to Cover Clinic Transportation Costs Improve Adherence and Retention in Care in a HIV Treatment Program in Rural Uganda. In: 17th Conference on Retroviruses and Opportunistic Infections San Francisco, CA; 2010. p. 16-9.
17. Etienne M, Burrows L, Osotimehin B, Macharia T, Hossain B, Redfield RR, *et al.* Situational analysis of varying models of adherence support and loss to follow up rates; findings from 27 treatment facilities in eight resource limited countries. *Trop Med Int Health* 2010;15 Suppl 1:76-81.